At the San Antonio Breast Cancer Symposium in December, Roche presented the data from its phase 3 Katherine trial, a head-to-head test of Kadcyla versus Herceptin in 1,500 patients.

Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease progressing.

U.S. health regulators granted a priority review for an experimental Roche breast cancer drug that in clinical trials added six months to the time before the disease worsened.

As its oncology stalwart Herceptin prepares for a rush of biosimilar competitors, Roche has high hopes for another horse in the HER2-positive breast cancer space. And now, Kadcyla’s ready to run ...

Swiss drugmaker Roche said on Tuesday its Tecentriq medicine will get a speedy review by U.S. regulators in a tough-to-treat form of breast cancer, as it seeks to be the first company to have its ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new survival data to be presented at the upcoming ASCO congress looks set ...

FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation F. Hoffmann-La Roche Ltd Wed, May 29, 2024, 1:00 AM 11 ...

The Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that could soon become the first pharmaceutical option approved for treating early-stage disease ...

Pharmaceutical company Roche has submitted an application to the U.S. FDA for its antibody-drug trastuzumab-DM1, which could replace its Herceptin remedy for women with advanced breast cancer.